FDA's draft guidance on chronic fatigue syndrome used patient input to provide an answer to one of the big questions that companies and clinical investigators have not been able to answer on their own: primary endpoints assessing symptom improvement are preferred to functional endpoints.

The document also says sponsors should use well-defined and reliable patient-reported outcome (PRO) instruments to measure improvement in symptoms.